The drug ARV-471, now known by its generic name vepdegestrant and brand name VEPPANU, has made history. As of May 1, 2026, it became the first-ever PROTAC (Proteolysis-Targeting Chimera) to receive FDA approval.
Discovered through the pioneering work at Arvinas and detailed in seminal research such as the Journal of Medicinal Chemistry paper(https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01818), vepdegestrant represents a paradigm shift in how we treat hormone-driven cancers.For decades, the standard of care for ER+ breast cancer has been focused on “blocking” the Estrogen Receptor (ER). However, tumors are smart; they often develop mutations (specifically in the ESR1 gene) that make the receptors active even without estrogen, rendering traditional blockers like fulvestrant less effective.
Enter VEPPANU, a molecular “vacuum cleaner” that doesn’t just block the receptor—it deletes it.
1. The Mechanism: How a PROTAC Works
Unlike traditional drugs that bind to a protein to inhibit its function, VEPPANU is a heterobifunctional molecule. Think of it as a double-sided connector:
Side A binds specifically to the Estrogen Receptor (ER).
Side B binds to an E3 ubiquitin ligase (specifically VHL).
By bringing these two together, VEPPANU tricks the cell into “tagging” the Estrogen Receptor with ubiquitin. Once tagged, the cell’s natural disposal system—the proteasome—shreds the receptor into harmless amino acids. This “event-driven” pharmacology allows a single molecule of VEPPANU to destroy multiple receptors, one after another.
2. From the Lab to the Clinic
The initial discovery (as outlined in J. Med. Chem.) highlighted several “hero” traits of the molecule:
Potent Degradation: In MCF7 breast cancer cell lines, vepdegestrant achieved a half-maximal degradation concentration ($DC_{50}$) of just 1.8 nM.
Oral Bioavailability: While the previous gold standard for degradation (fulvestrant) requires painful monthly intramuscular injections, VEPPANU is a once-daily oral pill.
Mutant Power: Most importantly, non-clinical studies showed it was just as effective at degrading the “resistant” ESR1 mutations (like Y537S and D538G) as it was at degrading the wild-type receptor.
3. The VERITAC-2 Triumph
The FDA approval was granted based on the pivotal Phase 3 VERITAC-2 trial, which compared VEPPANU to fulvestrant in patients who had already progressed on other therapies.
Key Results for ESR1-Mutant Patients:
| Metric | VEPPANU (Vepdegestrant) | Fulvestrant (Control) |
| Median PFS | 5.0 Months | 2.1 Months |
| Risk Reduction | 43% Lower | – |
| Objective Response | 19% | 4% |
4. Safety and Considerations
Because VEPPANU is a first-in-class therapy, its safety profile was closely monitored. The 2026 FDA label includes several key warnings:
QTc Prolongation: Patients with a history of heart rhythm issues should be monitored closely.
Embryo-Fetal Toxicity: As with many potent oncology drugs, it can cause harm to a developing fetus.
Common Side Effects: These include decreased white blood cell counts, nausea, and musculoskeletal pain (a side effect likely linked to the systemic removal of estrogen receptors).
5. What This Means for the Future
The approval of VEPPANU is a “proof of concept” for the entire PROTAC field. It validates that we can now target proteins that were previously considered “undruggable.” Arvinas and their partner Pfizer have already signaled that this is just the beginning, with more degraders in the pipeline for neurodegenerative diseases and other cancers.